Indication intelligence, analysis and sector perception

MiMedx (MDXG) positive data P2B clinical trial Of AmnioFix® Injectable In treatment Of Plantar Fasciitis

March 26, 2018 10:02am

AmnioFix Injectable achieved primary and secondary efficacy endpoints; along with stock jumping +$0.23 or +3.44%

MiMedx Group, Inc. (MDXG) announced positive pain and foot function results from its Phase 2B clinical trial of AmnioFix® Injectable in the treatment of Plantar Fasciitis.

The P2B IND clinical trial evaluating the use of AmnioFix Injectable for the treatment of Plantar Fasciitis demonstrated a clinically and statistically significant difference compared to patients in the Control Group in their reduction in the visual analog scale (VAS) score for pain (p<0.0001) and Foot Function Index-Revised (FFI-R) scores (p=0.0004) at 3 months compared to baseline.

Additionally, the safety of the product was demonstrated by the absence of serious, unanticipated, product-related adverse events and the relative absence of an elicited immune response post-injection demonstrated by the Treatment Group.

Now, they just have to get the “accounting” issues resolved, shuffle a few execs and get the stock back where it should be …!

Plantar Fasciitis is the most common cause of chronic heel pain in adults, comprising 11–15% of the foot symptoms requiring professional care among adults, according to studies published in the Journal of Research in Medical Sciences. It is estimated that 1 in 10 people will develop Plantar Fasciitis during their lifetime, with approximately one million people per year seeking medical treatment. The Company believes 60% of these patients could be potential candidates to receive AmnioFix Injectable, which MiMedx estimates represents a $450 million annual market opportunity for the Company.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.